TrialLeukemia2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
E Terpos et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled ittrialcites it